Mechanisms of Allergen Immunotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01523158
Recruitment Status : Terminated (R and D approval not forthcoming)
First Posted : February 1, 2012
Last Update Posted : September 25, 2012
Information provided by (Responsible Party):
Nicola Gray, Royal Sussex County Hospital

Brief Summary:

Hay fever (seasonal allergic rhinitis) results from allergy to grass and tree pollen. The majority of affected individuals manage well with medication from the Pharmacy or from their general practitioner (GP), but for some severely affected people it severely impacts on quality of life. Less than 40% of those affected in UK general practice feel that these medications achieve good symptomatic control.

Specific immunotherapy or desensitisation is the practice of administering small amounts of allergen to allergic patients in increasing doses. This treatment is highly effective in these patients and furthermore is truly disease-modifying, with benefits persisting long-term, even when the treatment has been completed. Desensitisation is a routine treatment in the UK, Europe and North America. The exact immune mechanisms that underlie this symptomatic improvement are not entirely clear. Dr Tarzi, Professor Frew and Professor Kern have recently developed new methods for the investigation of immune responses to allergens. These methods require relatively small blood samples and may provide useful information about how immunotherapy exerts its effects. In addition to improving the investigators basic understanding of this treatment, such knowledge may drive improvements in the treatment and could be useful for monitoring patients for response. The investigators study proposes to investigate changes in the immune responses to pollen allergens during immunotherapy. Blood will be taken just prior to the first immunotherapy injection and again just prior to the final injection. In this way the investigators will be able to compare the immune responses to pollen allergen before and after treatment.

Condition or disease Intervention/treatment Phase
Allergic Rhinitis Biological: Allergovit grass or birch Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: An Open Study to Investigate the Effects of Injection Immunotherapy on Allergen-specific T and B Cell Responses in Adult Patients With Seasonal Allergic Rhinitis.
Study Start Date : April 2012
Estimated Primary Completion Date : June 2015
Estimated Study Completion Date : September 2015

Arm Intervention/treatment
Open label study of changes to cellular responses following immunotherapy
Biological: Allergovit grass or birch
subcutaneous injection of immunotherapy once weekly for 7 weeks prior to birch pollen season.

Primary Outcome Measures :
  1. What are the changes in T cells associated with immunotherapy? [ Time Frame: 6 months ]
    How does the T cell response change after immunotherapy

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female
  • Age 18 with no upper age limit
  • History of seasonal rhino-conjunctivitis in the appropriate season, not controlled by optimised standard medical therapy
  • Positive skin prick test to grass pollen or tree pollen

Exclusion Criteria:

  • Inadequately controlled or moderate to severe asthma (GINA III/IV), i.e. the FEV1 is below 70 % of the target value despite adequate pharmacotherapy
  • Irreversible changes in the reaction organ (emphysema, bronchiectasis, etc.)
  • Clinically significant cardiovascular insufficiency (in cardiovascular diseases, there is an elevated risk of adverse reactions to adrenaline)
  • Local or systemic use of beta blockers
  • Diseases of the immune system (autoimmune diseases, immune complex-induced immunopathies, immunodeficiencies etc.)
  • Malignant disease within the past five years (Patients with previous malignant disease that is considered cured may be included subject to the consent of their oncologist)
  • Inability to attend regularly for injections and follow-up visits
  • Severe atopic dermatitis
  • Pregnant or not using adequate contraception (post-menopausal, surgically sterilised, long-term abstinent, or barrier methods plus spermicide)
  • Breast-feeding
  • Evidence of current drug or alcohol misuse
  • Hypersensitivity to any of the SIT (immunotherapy product) excipients
  • Active tuberculosis
  • Severe mental disorders
  • Multiple sclerosis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01523158

United Kingdom
Royal Sussex County Hospital
Brighton, United Kingdom, BN2 5BE
Sponsors and Collaborators
Royal Sussex County Hospital

Responsible Party: Nicola Gray, Clinical Research Fellow, Royal Sussex County Hospital Identifier: NCT01523158     History of Changes
Other Study ID Numbers: 12/014/TAR
First Posted: February 1, 2012    Key Record Dates
Last Update Posted: September 25, 2012
Last Verified: September 2012

Keywords provided by Nicola Gray, Royal Sussex County Hospital:
Allergic Rhinitis

Additional relevant MeSH terms:
Rhinitis, Allergic
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases